Healthpeak Properties, Inc. · DOC · FY2025 Q4 · Calendar Q1 2026

Healthpeak posts solid Q4 as lab pressure persists

Healthpeak’s current analysis supports a constructive but conditional view: outpatient medical and senior housing provide operating momentum, while lab recovery and capital-allocation execution remain unresolved.

Reported After market closeNYSEReal Estate $13.40B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $0.47 Consensus $0.45
EPS surprise +4.4% Reported versus consensus
Reported revenue $704.8M Consensus $691.6M
Revenue surprise +1.9% Reported versus consensus

Market reaction

event-close to next-session close
Stock move -2.8% Event window
SPY move -0.8% Same window
Abnormal move -1.9% Stock minus SPY
Volume 1.9× Versus trailing sessions
Subsequent drift +7.3% Up to 20 sessions
DOCSPY benchmark

Ask FN2 about DOC FY2025 Q4

Transcript, numbers and history already loaded

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

Relative to the prior quarter, the narrative shifted from anticipated occupancy pressure and capital recycling toward a more defined portfolio strategy: outpatient leasing remained strong, senior housing was positioned for a REIT transition, and management highlighted acquisitions, technology, and merger synergies. Lab pressure persisted.

Guidance delta

Management maintained guidance. The current analysis points to continued lab pressure alongside stronger outpatient and senior-housing performance.

Key takeaways

  • Outpatient medical remained the strongest operating area, with record leasing activity and solid asset sales.
  • Lab performance remained pressured, although management cited improving capital-raising conditions and pipeline activity as possible recovery signals.
  • Senior housing was a major growth area and is planned for transfer into the Janus Living REIT.
  • Management emphasized acquisition, capital recycling, merger synergies, and technology initiatives as parts of the growth plan.
  • The balance sheet supports the strategy, while lab occupancy, refinancing, and execution remain important risks.

Management priorities

  • Advance the Janus Living IPO and senior-housing asset transition.
  • Pursue acquisitions and recycle assets while maintaining disciplined capital allocation.
  • Continue internalizing property management and capturing merger synergies.
  • Deploy automation and technology to improve operating efficiency.
  • Execute redevelopment and tenant-improvement projects across the portfolio.

Follow DOC with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
DOC REVENUE earnings history estimate and actual scatter chart 9 reported fiscal quarters and 3 future estimate-only quarters. Q4 '23 estimate $139M Q4 '23 actual $135M, miss Q1 '24 estimate $669M Q1 '24 actual $607M, miss Q2 '24 estimate $682M Q2 '24 actual $696M, beat Q3 '24 estimate $686M Q3 '24 actual $700M, beat Q2 '25 estimate $702M Q2 '25 actual $694M, miss Q3 '25 estimate $685M Q3 '25 actual $706M, beat Q4 '25 estimate $692M Q4 '25 actual $705M, beat Q1 '26 estimate $695M Q1 '26 actual $739M, beat Q2 '26 estimate $726M Q2 '26 actual $750M, beat Q3 '26 estimate $748M Q4 '26 estimate $735M Q1 '27 estimate $750M
Show less

Analyst Consensus ?

ConsensusHold39 ratings
Bullish1948.7%
Neutral2051.3%
Bearish00.0%

1 unmapped firm rating excluded from the percentages.

Analyst 52W Price Targets

$19.44Current
$15Low
$20.92Average
$28High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 2, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Evercore ISI Group In Line In LineMaintainSep 21, 2026
Barclays Equal Weight Equal WeightMaintainAug 31, 2026
Baird Outperform OutperformMaintainAug 13, 2026
Citigroup Neutral NeutralMaintainAug 11, 2026
RBC Capital Outperform OutperformMaintainAug 10, 2026
Show 35 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $19.44. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
JefferiesAnalyst unavailable$21$20.37 +8.0%Sep 15, 2026
BarclaysAnalyst unavailable$24$20.96 +23.5%Aug 31, 2026
Cantor FitzgeraldRichard Anderson$23$21.52 +18.3%Aug 6, 2026
Wells FargoAnalyst unavailable$22$21.66 +13.2%Jul 15, 2026
BarclaysAnalyst unavailable$23$21.75 +18.3%Jul 7, 2026
See 34 more

Track every rating change on DOC the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Healthpeak Properties, Inc. is an S&P 500 constituent operating as a fully integrated real estate investment trust (REIT). The firm is dedicated to the acquisition, management, and development of premier properties essential for both medical research and the provision of healthcare services.

Historical context

All DOC earnings

Latest beats and misses

Who reports next

Get the DOC recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:36:15.940040+00:00
  3. Polygon adjusted daily market bars · 2026-10-02T04:06:06.352721+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-02T04:06:06.349987+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-02. For educational purposes only; not investment advice.